Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics, alleging that the company made materially false and misleading statements regarding its drug candidate SLK and its comparison to BIMZELX [1]. Group 1: Allegations - The lawsuit claims that during the class period from March 10, 2024, to September 29, 2025, the defendants failed to disclose that SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F [1]. - It is alleged that SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. - The complaint states that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, undermining the defendants' positive statements about SLK's superiority [1]. - The lawsuit argues that the defendants lacked a reasonable basis for their optimistic claims regarding SLK compared to monoclonal antibodies [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased MLTX shares during the specified class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177687&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Cann ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Viewpoint - MoonLake Immunotherapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a higher clinical response for patients, suggesting a competitive advantage over traditional monoclonal antibody treatments [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the Phase 3 VELA trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [7].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [3]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [3]. Group 2: Next Steps for Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a well-established securities litigation firm, has a strong track record in securing recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to a significant stock price drop [1][3][4]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. Group 3: Stock Performance Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's lack of competitive efficacy, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Accessibility StatementSkip Navigation WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025Â to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the pas ...

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [7].